Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who's Online
There are currently, 57 guest(s) and 6 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!


ThisIsMS.com :: View topic - OxyPharma Announces Selection of MS Drug
 Forum FAQForum FAQ   SearchSearch   UsergroupsUsergroups   ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 


OxyPharma Announces Selection of MS Drug

 
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Drug Pipeline
View previous topic :: View next topic  
Author Message
LindaR
Family Member


Joined: Nov 10, 2004
Posts: 88
Location: USA - Connecticut

PostPosted: Fri Apr 08, 2005 8:19 am    Post subject: OxyPharma Announces Selection of MS Drug Reply with quote

Found this on the internet.

OxyPharma Announces Selection of Multiple Sclerosis (MS) Drug Development Candidate

STOCKHOLM, Sweden, April 5, 2005--Swedish drug development company OxyPharma has selected a candidate drug (CD) for the treatment of multiple sclerosis (MS) from its autoimmune diseases drug discovery program. The selected compound, Rob 895, is now ready to go into a full-scale pre-clinical program.

Rob 895 has been developed from OxyPharma's patented lead compound B-220, from which OxyPharma has developed several analogue substances, which in animal studies have shown very promising results for the treatment of both MS and rheumatoid arthritis (RA).

Based on the successful completion of the pre-clinical program for Rob 895, OxyPharma intends to submit a regulatory filing for the initiation of first-time-in-human clinical studies.

The selected compound (Rob 895) is the second drug candidate arising from OxyPharma's drug discovery program. Last year, OxyPharma selected Rob 803 as its candidate drug for the treatment of RA. OxyPharma is currently conducting toxicological studies of Rob 803 and intends to start Phase IIa clinical studies of the compound in early 2006.

Additional research has demonstrated Rob 895 to be a more attractive drug candidate than the lead compound for pharmaceutical development due to properties that include improved potency, tolerability, pharmacokinetics and pharmaceutics.

MS is a chronic, inflammatory condition to the nervous system afflicting approximately 2.5 million people worldwide. Most patients diagnosed with MS are between the ages of 30 and 50, and the disease has a medium duration of more than 30 years. The value of the MS market was USD 3.5bn in 2003, and is growing rapidly.


At present, there are no effective, safe and easily administrated drugs for the treatment of neither MS nor RA. Animal studies indicate that OxyPharma's small molecule substances can be effective, easy to administrate orally and may be produced at low cost compared to present alternatives for the treatment of both diseases.


About OxyPharma:


OxyPharma is a Swedish drug development company developing new drugs primarily for the treatment of Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). The development of the drugs are done in collaboration with e.g. the Karolinska Institute in Sweden and contract research organizations (CRO's) in England, Sweden and Israel. OxyPharma was founded in 2002 and is based in Stockholm, Sweden. The company's largest shareholder is innovator and entrepreneur Leif Lundblad. Ulf Björklund is OxyPharma's CEO.


OxyPharma is presently conducting a financing round of SEK 80-130m aimed at primarily European investors. The objective is to secure the midterm need for operative capital to further develop OxyPharma's RA and MS drugs (e.g. by clinical studies).


For additional information please contact:

Ulf Björklund CEO, OxyPharma AB Phone: +46 8 726 17 02 or +46 70 667 04 40

Email: ulf.bjorklund@oxypharma.com

or


Peter Karaszi Press Officer, OxyPharma AB Phone: +27 21 439 8806 or +27 83 243 5797
Back to top
View user's profile Send private message Send e-mail
Outlawbiker
Family Member


Joined: Oct 06, 2004
Posts: 38
Location: Upstate New York

PostPosted: Fri Apr 08, 2005 11:26 am    Post subject: As far as I'm concerned... Reply with quote

Oral is always better in my book Wink

God, I hate needles!
Back to top
View user's profile Send private message Send e-mail
LindaR
Family Member


Joined: Nov 10, 2004
Posts: 88
Location: USA - Connecticut

PostPosted: Fri Apr 08, 2005 1:21 pm    Post subject: Reply with quote

I agree with you to G, oral is always better. Hate those pricks!
(oink)
Back to top
View user's profile Send private message Send e-mail
treez
Family Elder


Joined: Jul 28, 2004
Posts: 128
Location: Michigan, USA

PostPosted: Fri Apr 08, 2005 6:39 pm    Post subject: Reply with quote

Don't mind the pricks, just need effectiveness.

30-35% just doesn't cut it!
Confused

Treez
Back to top
View user's profile Send private message
deehammer
Getting to Know You...


Joined: May 24, 2004
Posts: 13
Location: Klamath Falls, Oregon

PostPosted: Fri Apr 15, 2005 2:58 am    Post subject: Reply with quote

I agree with Treez, it gotta be really effective, but I'd also prefer oral to shots. I don't think that I'll ever get use to the shots and I've been doing this for 4 years.
Dena



Smile
Back to top
View user's profile Send private message Send e-mail AIM Address Yahoo Messenger
HarryZ
Family Elder


Joined: May 26, 2004
Posts: 1383
Location: London, ON, Canada

PostPosted: Fri Apr 15, 2005 8:31 pm    Post subject: Re: OxyPharma Announces Selection of MS Drug Reply with quote

Linda,

Quote:
At present, there are no effective, safe and easily administrated drugs for the treatment of neither MS nor RA.


Hmmm...I wonder what the CRAB drug companies would have to say about this statement by Oxypharma?!!! Not that I disagree with the comment but I'm sure it would ruffle a few feathers.

Harry
Back to top
View user's profile Send private message Send e-mail
Display posts from previous:   
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Drug Pipeline All times are GMT - 6 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum





We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project. Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS, on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!

Experience Project: I have Multiple Sclerosis


Anonymous Confessions | Free Dream Interpretations | Ask Any Question
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002-8 by thisisMS.com.
PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Page Generation: 0.11 Seconds